fucidin 250 mg
leo pharma - fusidinsyre - tablett, filmdrasjert - 250 mg
fucidin-hydrocortison 20 mg/ g / 10 mg/ g
leo pharma - fusidinsyrehemihydrat / hydrokortisonacetat - krem - 20 mg/ g / 10 mg/ g
finacea 15 %
leo pharma a/s (danmark) - azelainsyre - gel - 15 %
kaleorid 750 mg
leo pharma - kaliumklorid - depottablett - 750 mg
skinoren 20 %
leo pharma a/s (danmark) - azelainsyre - krem - 20 %
protopic
leo pharma a/s - takrolimus - dermatitt, atopisk - andre dermatologiske preparater - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. forekommer fire ganger eller mer per år) som har hatt et første svar til maksimalt seks uker behandling av to ganger daglig takrolimus salve (lesjoner ryddet, nesten ryddet eller mildt rammet).
kyntheum
leo pharma a/s - brodalumab - psoriasis - immunsuppressive - kyntheum er indisert for behandling av moderat til alvorlig plakspsoriasis hos voksne pasienter som er kandidater til systemisk terapi.
adtralza
leo pharma a/s - tralokinumab - dermatitt, atopisk - andre dermatologiske preparater - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
adenosin life medical 5 mg/ ml
evolan pharma ab - adenosin - injeksjons-/infusjonsvæske, oppløsning - 5 mg/ ml